Literature DB >> 7346530

Intrasubject variation in sustained-release theophylline absorption.

R A Dederich, S J Szefler, E R Green.   

Abstract

Intrasubject variability in the absorption characteristics of two sustained-release theophylline products was examined. Eight healthy, nonsmoking, adult volunteers received a single 250 mg Slo-Phyllin Gyrocap on two separate study days and a single 300 mg Theo-dur tablet on two other study days. Plasma samples were collected over a 24-hr period after each dose and were assayed for theophylline content. Absorption parameters were determined, including peak plasma concentration, peak time, absorption rate, time until 90% absorbed, and area under the plasma concentration time curve. Marked intrasubject variation in these absorption parameters was found by examination of duplicate plasma concentration times curves. These differences are not apparent from examination of mean data only. The implications of this dose-to-dose variation for the individual patient are discussed.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7346530     DOI: 10.1016/0091-6749(81)90100-7

Source DB:  PubMed          Journal:  J Allergy Clin Immunol        ISSN: 0091-6749            Impact factor:   10.793


  15 in total

1.  Adenosine receptor-dependent signaling is not obligatory for normobaric and hypobaric hypoxia-induced cerebral vasodilation in humans.

Authors:  Ryan L Hoiland; Anthony R Bain; Michael M Tymko; Mathew G Rieger; Connor A Howe; Christopher K Willie; Alex B Hansen; Daniela Flück; Kevin W Wildfong; Mike Stembridge; Prajan Subedi; James Anholm; Philip N Ainslie
Journal:  J Appl Physiol (1985)       Date:  2017-01-12

2.  Intra- and inter-subject variabilities of CGP 33101 after replicate single oral doses of two 200-mg tablets and 400-mg suspension.

Authors:  W K Cheung; F Kianifard; A Wong; J Mathieu; T Cook; V John; E Redalieu; K Chan
Journal:  Pharm Res       Date:  1995-12       Impact factor: 4.200

3.  Bioavailability estimation by semisimultaneous drug administration: a Monte Carlo simulation study.

Authors:  M O Karlsson; U Bredberg
Journal:  J Pharmacokinet Biopharm       Date:  1990-04

4.  Intra- and intersubject variability: mixed-effects statistical analysis of repeated doses of an angiotensin converting enzyme inhibitor, CGS 16617.

Authors:  G M Kochak; R A Smith; R L Choi; V John; V Tipnis; F Honc; J K deSilva; D J Weidler
Journal:  Pharm Res       Date:  1989-04       Impact factor: 4.200

Review 5.  Acute overdose with sustained release drug formulations. Perspectives in treatment.

Authors:  A Minocha; D A Spyker
Journal:  Med Toxicol       Date:  1986 Jul-Aug

Review 6.  Theophylline.

Authors:  E F Ellis
Journal:  Clin Rev Allergy       Date:  1983-03

7.  Once a day theophylline; serum concentrations.

Authors:  V Nerminathan; S A McKenzie
Journal:  Arch Dis Child       Date:  1984-08       Impact factor: 3.791

Review 8.  A clinical and pharmacokinetic basis for the selection and use of slow release theophylline products.

Authors:  L Hendeles; R P Iafrate; M Weinberger
Journal:  Clin Pharmacokinet       Date:  1984 Mar-Apr       Impact factor: 6.447

Review 9.  Theophylline poisoning. Pharmacological considerations and clinical management.

Authors:  P Gaudreault; J Guay
Journal:  Med Toxicol       Date:  1986 May-Jun

10.  The influence of antacid on the absorption of two different sustained-release formulations of theophylline.

Authors:  K I Myhre; R A Walstad
Journal:  Br J Clin Pharmacol       Date:  1983-06       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.